Pemphigus is divided into two major subtypes: pemphigus vulgaris and pemphigus foliaceus. Oral corticosteroids are the primary treatment modality for pemphigus, while other therapeutic options ...

An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.

The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.

This is a schematic of how a "chimeric autoantibody receptor," or CAAR, that displays fragments of the autoantigen Dsg3 helps fight an autoimmune disease called pemphigus vulgaris, a condition in ...

Pemphigus vulgaris is an autoimmune where the immune system produces antibodies against proteins in the skin and mucous membranes. Antibodies break bonds between cells leading to formation of skin ...

The new data is important for rilzabrutinib's prospects, as the drug previously fell short in a phase 3 trial involving patients with pemphigus vulgaris, as well as a phase 2 study in atopic ...